Equities

Standard BioTools Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Standard BioTools Inc

Actions
  • Price (EUR)0.945
  • Today's Change0.000 / 0.00%
  • Shares traded100.00
  • 1 Year change-28.95%
  • Beta1.3654
Data delayed at least 15 minutes, as of Feb 17 2026 07:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2024202420232022
ASSETS
Cash And Short Term Investments293115166
Total Receivables, Net342017
Total Inventory412121
Prepaid expenses8.663.133.26
Other current assets, total----1.02
Total current assets376158209
Property, plant & equipment, net715560
Goodwill, net111106106
Intangibles, net291.4113
Long term investments------
Note receivable - long term------
Other long term assets231.481.53
Total assets612323390
LIABILITIES
Accounts payable129.247.91
Accrued expenses372519
Notes payable/short-term debt000
Current portion long-term debt/capital leases0602.08
Other current liabilities, total171614
Total current liabilities6610943
Total long term debt0.303.9863
Total debt0.306465
Deferred income tax1.080.841.06
Minority interest------
Other liabilities, total734653
Total liabilities141160161
SHAREHOLDERS EQUITY
Common stock0.400.080.08
Additional paid-in capital1,702861847
Retained earnings (accumulated deficit)(1186)(1001)(926)
Treasury stock - common(46)(5.98)(0.56)
Unrealized gain (loss)----(0.5)
Other equity, total1.23(2.22)(1.39)
Total equity472163230
Total liabilities & shareholders' equity612323390
Total common shares outstanding3788079
Treasury shares - common primary issue193.130.42
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.